FMP
HilleVax, Inc.
HLVX
NASDAQ
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
13.28 USD
0.49 (3.69%)
About
ceo
Dr. Robert M. Hershberg M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.hillevax.com
exchange
NASDAQ
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
CIK
0001888012
ISIN
US43157M1027
CUSIP
43157M102
Address
75 State Street
Phone
617 213 5054
Country
US
Employee
90
IPO Date
Apr 29, 2022
Key Executives
